Economic Impact of Reducing Hospital Admissions for Patients Presenting to the Emergency Department With Worsening Heart Failure: An Adaptive Clinical Trial of Furoscix Infusor

Trial Profile

Economic Impact of Reducing Hospital Admissions for Patients Presenting to the Emergency Department With Worsening Heart Failure: An Adaptive Clinical Trial of Furoscix Infusor

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Mar 2018

At a glance

  • Drugs Furosemide (Primary) ; Furosemide
  • Indications Heart failure
  • Focus Therapeutic Use
  • Acronyms FREEDOM-HF
  • Sponsors scPharmaceuticals
  • Most Recent Events

    • 20 Mar 2018 According to scPharmaceuticals Inc media release, Company expects to begin enrollment in the second quarter of 2018 and Data from this trial is expected by the end of 2018
    • 14 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top